A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

Condition(s) studied

Investigational drug(s) / intervention(s)

ALN-4324: ALN-4324 will be administered subcutaneously (SC)

Placebo: Placebo will be administered SC

Study summary

The purpose of this study is to:

* evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324
* evaluate the efficacy, safety, tolerability, PK, and pharmacodynamics (PD) of multiple doses of ALN-4324 in adult overweight to obese patients with T2DM

Eligibility

Primary outcome measure(s)

• Part A: Frequency of Adverse Events (AEs) — Up to 9 months
• Part B: Frequency of Adverse Events — Up to 12 months

Trial sites (22)